+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Axitinib"

Kidney Cancer Drugs Global Market Report 2024 - Product Thumbnail Image

Kidney Cancer Drugs Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Renal Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Renal Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 180 Pages
  • Global
From
From
From
Inlyta (axitinib; Pfizer) Drug Overview 2019 - Product Thumbnail Image

Inlyta (axitinib; Pfizer) Drug Overview 2019

  • Report
  • March 2019
  • 20 Pages
  • Global
Torisel (temsirolimus; Pfizer) Drug Overview 2019 - Product Thumbnail Image

Torisel (temsirolimus; Pfizer) Drug Overview 2019

  • Report
  • March 2019
  • 24 Pages
  • Global
From
  • 10 Results (Page 1 of 1)
Loading Indicator

Axitinib is a type of drug used to treat kidney cancer. It is a tyrosine kinase inhibitor, meaning it works by blocking certain proteins that help cancer cells grow and divide. Axitinib is used to treat advanced renal cell carcinoma, a type of kidney cancer. It is usually given after other treatments, such as surgery, have failed. Axitinib is usually taken orally, once a day. Common side effects include fatigue, diarrhea, nausea, and high blood pressure. Axitinib is one of several drugs used to treat kidney cancer. Other drugs used to treat kidney cancer include sunitinib, pazopanib, and cabozantinib. Each of these drugs works differently and has different side effects. Axitinib is marketed by Pfizer, Inc. Other companies that market drugs for kidney cancer include Novartis, Bristol-Myers Squibb, and Merck & Co. Show Less Read more